Robert Nathan Fried

Niagen Bioscience

Chief Executive Officer

President or CEO: Small-Midsize Company

Chief Executive Officer at Niagen Bioscience Robert Nathan Fried leads the organization’s strategic expansion across consumer wellness, clinical medicine and pharmaceutical innovation. Leveraging this record of success, he engineered a research-backed framework that scaled the enterprise’s external research program to surpass 300 academic agreements and generate over $100 million in third-party research. This expertise extends to managing a global licensing agreement advancing an NR-based therapy for Ataxia Telangiectasia and Parkinson’s Disease and supplying more than 1,200 clinics with pharmaceutical-grade formulations. Fried sustains this momentum by capitalizing on a decade of bioscience sector experience to oversee a high-profile telehealth platform launch. This leadership trajectory supports his prominent industry visibility, earning selection as an EY Entrepreneur Of The Year 2025 Greater Los Angeles award recipient. He previously orchestrated the strategic transition of the brand following the sale of Healthspan Research to ChromaDex. Fried successfully accelerated corporate fiscal performance to achieve $129.4 million in net sales and a debt-free position with $64.8 million in cash reserves.